Invention Grant
- Patent Title: IL2 and TNF immunoconjugates
-
Application No.: US16383444Application Date: 2019-04-12
-
Publication No.: US11274133B2Publication Date: 2022-03-15
- Inventor: Roberto De Luca , Francesca Pretto , Sarah Wulhfard
- Applicant: PHILOGEN S.P.A.
- Applicant Address: IT Siena
- Assignee: PHILOGEN S.P.A.
- Current Assignee: PHILOGEN S.P.A.
- Current Assignee Address: IT Siena
- Agency: Bozicevic, Field & Francis LLP
- Agent James S. Keddie
- Priority: GB1507908 20150508
- Main IPC: C07K14/525
- IPC: C07K14/525 ; C07K14/55 ; C07K16/18 ; A61K47/68 ; A61P35/00 ; A61K38/00
Abstract:
The present application relates to conjugates comprising interleukin 2 (IL2), and a tumour necrosis factor, such as tumour necrosis factor alpha (TNFα), and an antibody molecule. The antibody molecule preferably binds to an antigen associated with neoplastic growth and/or angiogenesis, such as the Extra-Domain A (EDA) of fibronectin. The conjugate may be used in the treatment of cancer.
Public/Granted literature
- US20190284253A1 IL2 and TNF Immunoconjugates Public/Granted day:2019-09-19
Information query
